christopher matthews(@sitiain66) 's Twitter Profile Photo

Myles McNulty Avacta People don’t appreciate the potential cost/profit of this drug. Keytruda is £84000 per patient .Dox/many chemo are off patent so are cheap.Avacta drugs won’t be . Chemo is still one of the most efficient drugs there is. Make it safe and it’s a cancer game changer, beyond exciting

account_circle
Sue Veach ☮️(@butterflytxgirl) 's Twitter Profile Photo

My husband rang the bell today. Remission from Lung Cancer. He has benefited from the new drug Keytruda. We couldn’t be more grateful.

My husband rang the bell today. Remission from Lung Cancer. He has benefited from the new drug Keytruda. We couldn’t be more grateful.
account_circle
DiyDepot(@DiyDepotCo) 's Twitter Profile Photo

🦾Use the chain saw chain grinding fixture to make your chain saw as sharp as new, making your work more time-saving and labor-saving!

✨New 2023 chainsaw sharpener cleans dull chains quick and easy!

🛒shop now👉diydepots.co/product/chains…

account_circle
Gadgets Top(@Gadgetstop_co) 's Twitter Profile Photo

🧰Still sharpening chainsaw chains manually? Sharpen your chainsaw in 10 seconds without removing the chain.

✅Compatible with most brands of chainsaws
✅Polished in less than 5 seconds
✅Keeps saw chains lubricated and lasts longer

Get it👉excelgadgets.co/E7986

account_circle
NasdaqTurk(@NasdaqTurk) 's Twitter Profile Photo

$MRK
Merck, mide kanseri araştırması Keytruda için geç aşama denemelerinde başarısız olduğunu duyurdu

account_circle
ITDigest(@ITDigestmag) 's Twitter Profile Photo

KEYTRUDA Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Merck

lnkd.in/ddB_mHKC

KEYTRUDA Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
@Merck

lnkd.in/ddB_mHKC

#informationtechnology #news
account_circle
jojoabab(@jojoabab1) 's Twitter Profile Photo

Important information $ONCO Oncopeptides. The EMA process is now in a clock stop. Like Imjudo, Londurf, Keytruda which were recommended in June were also up in May under the same headline. Oncopeptides has decided to only communicate at the end of the EMA process.

account_circle
T-Mobile Business(@TMobileBusiness) 's Twitter Profile Photo

Building your own website is easy with today’s tools. Tips from expert Adesina Sanchez will help you make your DIY site look polished and professional.

Read her advice at : t-mo.co/422XAo0

Building your own #SmallBusiness website is easy with today’s tools. Tips from expert @AdesinaTV will help you make your DIY site look polished and professional. 

Read her advice at #MagentaEdge: t-mo.co/422XAo0
account_circle
christopher matthews(@sitiain66) 's Twitter Profile Photo

Nick Hargrave RAH Stephen Casey andrewsentance What about the price of treatment?. Keytruda world's leading cancer drug revenue I believe for Merke.$5.8 bio a 1/4.Uk £84000 per treatment.Dox off-patent is as cheap as chips. I wonder where they will price it?

account_circle
Mabbpah(@mabbpah) 's Twitter Profile Photo

So $NWBO has nothing to do with the combo-trial ( Keytruda + ATL-DC ) after all. I asked this question long back as NWBO's name was mentioned neither as a collaborator nor as a sponsor and you know how that conversation would have gone.

So $NWBO has nothing to do with the combo-trial ( Keytruda + ATL-DC ) after all. I asked this question long back as NWBO's name was mentioned neither as a collaborator nor as a sponsor and you know how that conversation would have gone.
account_circle
jojoabab(@jojoabab1) 's Twitter Profile Photo

Today June 22 is the day EMA will reveal if $ONCO will get L3+. The news is expected tonight after market close. On Monday the Stockholm market will open again. The L3+ market is 4 times the L4+ which Oncopeptides have now and all costs are fixed.

account_circle
Sam Klempner(@KlempnerSam) 's Twitter Profile Photo

Press release update on Keynote-811 and PD-L1+ subgroup (most patients in KN-811) businesswire.com/news/home/2023…

account_circle